

Technical Report 16



Epidemiology and clinical manifestations of COVID-19 during the early outbreak period based on reports from 10 countries

Nadeeka Perera^{1*}, Sumudu Avanthi Hewage², Nishani Fonseka¹, Chathurani Wickramaarachchi², Sajani Nadeeka³, Hemali Jayasekera¹, Sachintha Dilhani⁴, Mekala Fernando⁴, Chithramalee Rodrigo⁵, Thirumagal Sivashankar¹, Nadeeja Liyanage², Samantha Wijewardhane³, Surangi Jayakody⁶, Nuwan Darshana Wickramasinghe⁷, Shamini Prathapan⁶

¹ Family Health Bureau, Ministry of Health, Sri Lanka; ² National Programme for Tuberculosis and Chest Medicine, Ministry of Health, Sri Lanka; ³ Nutrition Division, Ministry of Health; ⁴ National Cancer Control Programme, Ministry of Health, Sri Lanka; ⁵ Non-Communicable Diseases Unit, Ministry of Health, Sri Lanka; ⁶ Department of Community Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka; ⁷ Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka

*Correspondence: nadeekayasanth@gmail.com

 <https://orcid.org/0000-0003-2725-3086>

DOI: <https://doi.org/10.4038/jccpsl.v26i5.8365>

Received on 22 May 2020

Accepted on 24 May 2020

Highlights

- Presentation of fever varied between 50-100% of cases at presentation.
- Some of the patients with COVID-19 were asymptomatic at diagnosis.
- Lack of local data on clinical presentation and management was a major limitation at the time of the survey.

Background

China has reported a cluster of cases of pneumonia in people linked with the Huanan Seafood Wholesale Market in Wuhan, Hubei Province since 8 December 2019. On 9 January 2020, Chinese health authorities confirmed that the cause of this viral pneumonia outbreak was a novel coronavirus, 2019-nCoV. This novel virus spread across Wuhan, which is a large city

located in Central China of more than 11 million people (1). The number of identified cases has been steadily growing over the following months from China and also from several other countries. COVID-19 has now been declared as a Public Health Emergency of International Concern by the World Health Organization (WHO). Given the spread of the novel coronavirus and its impact on human health, the research community has responded rapidly with

many preliminary articles already published. We have conducted a review to summarize the findings of these, with an aim to provide evidence on the epidemiology and clinical features of confirmed COVID-19 cases.

Compilation of the evidence

Literature for the review was identified by searching online databases such as Google Scholar and PubMed. Scientific publications in peer-reviewed journals from 10 countries as case reports/case series/descriptive studies or comparative studies on confirmed COVID-19 patients were included in the review. Data pertaining to the sociodemographic details, typical and atypical symptoms at presentation, past medical history, clinical course of disease were extracted.

Studies included in the review consisted of COVID-19 patients diagnosed by reverse transcription polymerase chain reaction (RT-PCR) except one study from China, which had compared 19 patients with COVID-19 positive pneumonia with 19 pneumonia patients who were negative for COVID-19 (2). One study from China reported 113 deceased patients confirmed with COVID-19 in Wuhan (3). Several other countries described the first cases reported from their country (4-9).

● Age and sex distribution

The age of patients varied from six months to ≥ 85 years. The majority belonged to the 40-50-year age group. In almost all studies, except for the individual case reports, the affected were mostly males.

● Clinical manifestation

COVID-19 confirmed patients had shown a wide spectrum of clinical manifestations ranging from mild to severe, with some leading to fatal complications.

The most commonly reported symptoms are fever, cough, fatigue or myalgia, sore throat (1-4, 10-17, 18), whereas less commonly reported symptoms were headache, diarrhoea, productive cough and

runny nose (3, 11-12, 15). Symptoms at presentation and during the course of the illness of confirmed cases are summarised below.

- Fever was present in 50-100% of the cases at presentation.

There were two case reports from Singapore and Germany, where the cases were asymptomatic at presentation (5, 19).

One study from China, which extracted data from 1099 patients reported fever in 43.8% on admission and 88.7% during hospitalization (1). Chills were reported in four studies (7, 18-20). According to one study in China, fever and cough were the dominant symptoms while gastrointestinal symptoms were uncommon, suggesting a difference in the viral tropism compared to SARS-CoV, MERS-CoV and seasonal influenza.

The absence of fever in COVID-19 was more frequent than in SARS-CoV (1%) and MERS-CoV infection (2%). This highlights that afebrile patients could be missed if the surveillance case definition focuses on fever detection (1).

- The presentation of cough varied between 47-81% (1-6, 8, 12, 14-15, 18, 21-22). Several studies specified it as a dry cough (6-7, 10, 12, 15) while a few reported it as an expectoration (13, 21).
- General malaise/myalgia was reported in five studies (3, 10, 18-19, 23), whereas fatigue was reported in three studies (2-4). One study reported that 50% had fatigue at presentation (3).
- Sore throat was reported in six studies and the percentage varied from 5% to 61%. (2, 3, 5, 10, 23). According to the case report from Germany, sore throat was present at the onset of symptoms but not at the stage of presentation to disease diagnosis (19).
- Shortness of breath was reported in six studies (3-5, 13, 15, 18). A Chinese study which reported data of 62 patients with mild disease, shortness of

breath was present only in 3% on admission (13). In three other studies, it was present in nearly 31% of the cases (3-4, 15). It was noted that at the time of presentation, shortness of breath had been reported in 62% (n=70) among those who died (n=113) and in 31%, (n=50) among those who recovered (n=161) (4).

- Rhinorrhoea or runny nose was reported in three studies and the percentage was less than 10% (3, 5, 7).
- Diarrhoea was reported in six studies and this percentage varied between 2-28% (3-5, 12-13, 15).
- Chest tightness was reported in three studies from China with a percentage varying from 2-38%. (2-4). It was noted that in one study, chest tightness was more commonly reported among those who eventually died (49%) than those who recovered (30%) (4).
- Headache, dizziness and even confusion had been reported in few studies (3-4, 12).

Clinical course and outcome

- According to a summary report of 72,314 cases from China, most cases were classified as mild (81% with no pneumonia or mild pneumonia), whereas 14% had severe (dyspnoea, blood oxygen saturation < 93%, lung infiltrates > 50%) and 5% were critical (respiratory failure, septic shock and multi organ failure) (24). The overall case fatality rate (CFR) was reported as 2.3%, however cases in those aged 70-79 years and 80 years and above were reported as 8.0% and 14.8%, respectively. No deaths were reported among mild and severe cases. The CFR was 49% among the critical cases and also increased with pre-existing comorbidities such as cardiovascular disease (10.5%), diabetes (7.3%) and chronic respiratory disease (6.3%) (24).
- The median (IQR) duration of days from onset of symptoms to hospital admission was 4.0 (1.0-

7.0) for those who recovered (1) and 10.0 (7.0-13.0) for those who succumbed to COVID-19 (4).

- The median (IQR) duration of days from the onset of symptoms to outcome was reported from 12.0 (95% CI=6.0-17.0) to 22.0 (95% CI=16.8, 27.3) (1-4, 8, 12).
- Those who required ICU care during the course of illness varied between 5-23%. The median (IQR) duration from the onset of symptoms to ICU admission was 9.5 (95% CI=7.0, 12.0) days (2-4).

Gaps in existing knowledge

The data had been collected mostly from available hospital records and in some studies the incomplete data had been collected referring to the treating healthcare workers, which could have included a recall bias. (1,4). Further, many patients were still at hospital, at the time of data extraction and as a result, some data would have been censored. They may have missed mild or asymptomatic patients who were not hospitalized. Further, the data were clinically driven and not systematic. The Sri Lankan studies or even South Asian studies related to clinical presentation of COVID-19 patients were rather scarce.

Public health implications

COVID-19 is a novel coronavirus, which emerged from China in December 2019 and which has spread to over 200 countries within four months, causing a massive pandemic. Since this is a new disease, knowledge is evolving day by day. Studying epidemiology and clinical presentation are key factors in identifying a disease. This would invariably help the epidemiologists in identifying the cases early, which would limit the spread in the community. Studying the course of the illness may help in deciding the treatment/management options, e.g. Can the mild/asymptomatic cases be observed in a separate centre or at even at home not burdening the main treatment centre? Lessons learnt from the countries that are successfully managing the disease

can be adopted after considering the individual country context.

Application of evidence to Sri Lanka

Most of the studies have collected data using standardized reporting formats such as International Severe Acute Respiratory and Emerging Infection Consortium case report forms. Using a common format and uploading the data at a common forum may increase the comparability of data, making it accessible to many stakeholders and preventing duplication of work.

In applying evidence to Sri Lanka, lack of data on clinical presentations is a major limitation for comparison. Thus, collecting and sharing data related to patient presentations, clinical course of the illness, treatment options etc. is common, yet a locally adaptive format, it would increase the usefulness of the data is a timely need. If the data can be entered to. Initially, the data obtained from the patients who were already discharged from hospital, would be helpful in decision making related to management options. It is recommended that the data be shared with relevant stakeholders (e.g. clinicians, public health experts, statisticians, etc.) whilst maintaining the ethical and administrative considerations.

Author Declaration

Acknowledgements: The authors acknowledge Professor Carukshi Arambepola, Department of Community Medicine, University of Colombo, Sri Lanka for her contribution in development of the data compilation matrix.

Author contributions: NP coordinated the data compilation and drafted the manuscript. SP, SJ, SAH and NDW were involved in conceptualization of the study and final editing of the manuscript. NP, NF, CW, SN, HJ, SD, MF, CR, TS, NL and SW were involved in data compilation.

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX ... & Du B. Clinical characteristics of coronavirus disease 2019 in China. *New England Journal of Medicine* 2020; 382: 1708 -1720. DOI: 10.1056/NEJMoa2002032.
2. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, Guo F, Zhao H, Gao R. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. *Clinical Infectious Diseases* 2020; ciaa247. DOI: 10.1093/cid/ciaa247.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020; 395(10223): 507-513. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).
4. Chen T, Wu D, Chen H, Yan W, Yang D, Ma K, Xu D, Chen G. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, *BMJ* 2020; 368: m1091. DOI: 10.1136/bmj.m1091.
5. Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA* 2020; 323(15): 1488-1494. DOI: 10.1001/jama.2020.3204.
6. Cheng SC, Chang YC, Chiang YL, Chien YC, Cheng M, Yang CH, Huang CH, Hsu YN. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan. *Journal of the Formosan Medical Association* 2020; 119(3): 747-751. DOI: 10.1016/j.jfma.2020.02.007.
7. National Institute of Infectious Diseases, Japan. *Case of first human-to-human infection of novel coronavirus in Japan*. National Institute of Infectious Diseases, 26 February 2020. Available from: <https://www.niid.go.jp/niid/en/2019-ncov-e/2488-idsc/iasr-news/9483-481p02-e.html>.
8. Park JY, Han MS, Park KU, Kim JY, Choi EH. First Pediatric Case of Coronavirus Disease 2019 in Korea. *Journal of Korean Medical Science* 2020; 35(11): e124. DOI: 10.3346/jkms.2020.35.e124.

9. Lillie PJ, Samson A, Li A, Adams K, Capstick R, Barlow GD, Easom N, Hamilton E, Moss PJ, Evans A, Ivan M, PHE Incident Team, Taha Y, Duncan CJA, Schmid ML, the Airborne HCID Network PII. Novel coronavirus disease (COVID-19): the first two patients in the UK with person to person transmission. *Journal of Infection* 2020; 80: 578-606. DOI: 10.1016/j.jinf.2020.02.020.
10. National Institute of Infectious Diseases, Japan. *Descriptive epidemiology of 287 confirmed cases of new coronavirus infection reported by the national epidemiological surveillance of infectious disease system (NESID) and active epidemiological surveillance*. National Institute of Infectious Diseases, 9 March 2020. Available from: <https://www.niid.go.jp/niid/en/2019-ncov-e/2484-idsc/9497-covid19-14-200309-e.html>.
11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020; 15; 395(10223): 507-513. DOI: 10.1016/S0140-6736(20)30211-7.
12. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J. ... & Zheng, C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases* 2020; 20(4): 425-434. DOI: 10.1016/S1473-3099(20)30086-4.
13. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, ... & Sheng JF. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020; 368: m606. DOI: 10.1136/bmj.m606.
14. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y ... & Wang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. *The Lancet Respiratory Medicine* 2020; 8(5): 475-481. DOI: 10.1016/S2213-2600(20)30079-5.
15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J ... & Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; 323(11): 1061-1069. DOI: 10.1001/jama.2020.1585.
16. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* 2020; 395(10223): 514. DOI: 10.1016/S0140-6736(20)30154-9.
17. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *Journal of Medical Virology* 2020; 92(4): 441-7. DOI: 10.1002/jmv.25689 date 27 Jan 2020.
18. Rahimzadeh G, Ekrami Noghabi M, Kadkhodaei Elyaderani F, Navaeifar MR, Enayati AA, Manafi Anari A, Hujati M, Rezai S, Rezai MS. COVID-19 infection in Iranian children: a case series of 9 patients. *Journal of Pediatrics Review* 2019; 8(2): 139-144. DOI: 10.32598/jpr.8.2.139.
19. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *New England Journal of Medicine* 2020; 382(10): 970-971. DOI: 10.1056/NEJMc2001468.
20. Kim JY. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR. *Journal of Korean Medical Science* 2019; 35(7): e88. DOI: 10.3346/jkms.2020.35.e88.
21. Park JY, Han MS, Park KU, Kim JY, Choi EH. First Paediatric Case of Coronavirus Disease 2019 in Korea. *Journal of Korean Medical Science* 2020; 35(11): e124. DOI: 10.3346/jkms.2020.35.e124.
22. Morbidity and Mortality Report. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States. *Morbidity & Mortality Weekly Report* 12 February-12 March 2020; 69: 343-346. DOI: 10.15585/mmwr.mm6912e22020.
23. Kim JY, Ko JH, Kim Y, Kim YJ, Kim JM, Chung YS, Kim HM, Han MG, Kim SY, Chin BS. Viral load kinetics of SARS-CoV-2 infection in first two

- patients in Korea. *Journal of Korean Medical Science* 2019; 27; 35(7): e86. DOI: 10.3346/jkms.2020.35.e86.
24. Wu Z & McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020; 323(13): 1239-1242. DOI: 10.1001/jama.2020.2648.